Doctors and biostatisticians at the University of Michigan Rogel Cancer Center have led the development and validation of a staging system to better predict outcomes and inform treatment decisions for men diagnosed with non-metastatic prostate cancer.

Although it is one of the most common cancers worldwide, prostate cancer remains one of the few major cancers for which the familiar, numerical staging system -- ranging from stage 1 to stage 4 -- has not been adopted into national guidelines for treatment or for the testing of new medicines in clinical trials.

Know more:https://www.sciencedaily.com/releases/2020/10/2010...